Coagulation and fibrinolysis in patients with resistance to thyroid hormone due to a thyroid hormone receptor β-gene mutation

Coagulation and fibrinolysis in patients with resistance to thyroid hormone due to a thyroid hormone receptor β-gene mutation - The THRβ study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38471

Enrollment

Registered

2013-12-12

Start date

2014-01-22

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insensitivity for thyroid hormone because of a change in the DNA thyroid hormone resistance because of a gene mutation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients with thyroid hormone resistance due to a mutation in the thyroid hormone receptor beta gene - Elevated T3 and/or T4 according to the local reference ranges;For the control groups: a) hyperthyroid patients with elevated serum T4 and/or T3 according to the local reference ranges b) euthyroid controls with general good health, both matched for age (± 5 years) and gender

Exclusion criteria

Exclusion criteria: - No informed consent - Oral anticoagulant therapy (warfarin, vitamin K antagonists) - Hemophilia or von Willebrand's disease - Oral corticosteroid therapy - Previous VTE within the last 6 months - Previous thyroid surgery or radio-iodine treatment - Current anti-thyroid drugs

Design outcomes

Primary

Measure	Time frame
The following groups of lab markers will be tested: labmarkers: thyroid function and SHBG, coagulation markers and fibrinolysis markers.	—

Countries

Netherlands

Outcome results